<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701374</url>
  </required_header>
  <id_info>
    <org_study_id>700PNC01</org_study_id>
    <nct_id>NCT02701374</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia</brief_title>
  <official_title>TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia —Double Blind Comparison With Placebo—</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Toray Industries, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Post-Herpetic Neuralgia(PHN) patients:

        -  To conduct an explorative investigation of the efficacy and safety of repeated oral
           doses of TRK-700 via a randomized double blind comparative study

        -  To measure the plasma concentration of TRK-700 and its metabolites
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average Numerical Rating Scale (NRS)</measure>
    <time_frame>baseline to week 8</time_frame>
    <description>Change in average NRS collected by Pain Diary from baseline to week 8 in subjects receiving TRK-700 versus Placebo</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Post-Herpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>1:TRK-700</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:TRK-700</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3:Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRK-700</intervention_name>
    <arm_group_label>1:TRK-700</arm_group_label>
    <arm_group_label>2:TRK-700</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>3:Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pain persisting for at least 3 months after the onset of herpes zoster

          -  Patients whose average pain score on the Numerical Rating Scale (NRS) over the past
             24 hours at preliminary enrollment is at least 4

        Exclusion Criteria:

          -  Patients with another skin disease that may affect the evaluation of the pain at the
             site of PHN

          -  Patients with pain other than PHN that may affect the evaluation of pain

          -  Patients with pain that is suspected to be mainly psychogenic

          -  Patients who have received neurolytic or neurosurgical therapy for PHN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TRK-700 Team</last_name>
    <phone>+81-3-3245-8570</phone>
    <email>Clinicaltrials-info@nts.toray.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Japan</name>
      <address>
        <city>Japan</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 17, 2016</lastchanged_date>
  <firstreceived_date>February 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRK-700</keyword>
  <keyword>Post-Herpetic Neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
